Results 21 to 30 of about 287,802 (318)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
New England Journal of Medicine, 2015 Alessandro Maria Vannucchi +2 more
exaly +2 more sources
Polisitemi Veralı Hastalarda Dinamik Thiol/Disulfit Dengesi ve İskemi Modifiye Albumin Düzeyleri
Düzce Tıp Fakültesi Dergisi, 2021 Aim: Polycythemia vera is a chronic myeloproliferative disease characterized by increased red cell mass and JAK2 mutation positivity. Transformation to myelofibrosis and acute leukemia is possible in patients with polycythemia vera.
Özcan Erel +8 more
doaj +1 more source
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Leukemia, 2021 Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that exceeds 35 years in young patients, but its natural history might be interrupted by thrombotic, fibrotic, or leukemic events, with respective 20-year rates of 26%,
A. Tefferi, A. Vannucchi, T. Barbui
semanticscholar +1 more source
Polycythemia vera presenting with pulmonary embolism and splenic infarction: a case report
Journal of International Medical Research, 2022 Pulmonary embolism and splenic infarction are rare in patients with polycythemia vera. We herein describe a man in his early 60s whose main symptoms were chest tightness, cough, and sputum expectoration.
Ping Huang, Yuhong Li
doaj +1 more source
Journal of Hematology & Oncology, 2021 In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten ...
F. Pimpinelli +18 more
semanticscholar +1 more source
Journal of Agromedicine and Medical Sciences (AMS), 2023 Polycythemia vera happened in people around 40-60 years old and mostly men. The criteria are total red blood cells ≥36 mL/kg in males, thrombocytosis, leukocytosis, and JAK2 mutation.
I Gusti Ayu Ratna Dewi +2 more
doaj +1 more source
Muramidase in Polycythemia Vera [PDF]
Blood, 1970 Abstract The serum muramidase levels of 45 patients with polycythemia vera were found to be significantly elevated above the values in 20 normal subjects. The patients with polycythemia vera who were studied included those with active disease, those controlled with myelosuppressive agents and those in the spent phase.
Richard A. Binder +2 more
openaire +3 more sources
American journal of hematology/oncology, 2020 Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding ...
A. Tefferi, T. Barbui
semanticscholar +1 more source
Anesthetic management of a patient with polycythemia vera undergoing emergency repair of a type-A aortic dissection and concomitant coronary artery bypass grafting: a case report [PDF]
Korean Journal of Anesthesiology, 2015 Polycythemia vera is a chronic progressive myeloproliferative disease characterized by increased circulating red blood cells, and the hyperviscosity of the blood can lead to an increased risk of arterial thrombosis.
Hyeongwoo Im +4 more
doaj +1 more source
Aberrant expression of microRNA in polycythemia vera
Haematologica, 2008 Background Polycythemia vera is a clonal hematopoietic stem cell disorder in which the JAK2 V617F mutation is observed in >95% of patients, but an as yet unidentified process appears to initiate the clonal expansion of hematopoiesis.
Hana Bruchova +2 more
doaj +1 more source